Navigation Links
Labopharm announces change to Board of Directors
Date:11/7/2008

LAVAL, QC, Nov. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that Rachel R. Selisker has been appointed to the Board of Directors of the Company to fill the vacancy created by the resignation of James S. Scibetta, who has stepped down for personal reasons. Ms. Selisker will also replace Mr. Scibetta as Chairman of the Audit Committee. Ms. Selisker, a Certified Public Accountant, will bring senior financial advisory expertise in the healthcare industry as well as more than 13 years of experience as chief financial officer of a high growth, international pharmaceutical services company.

Santo J. Costa, Chairman of the Board of Directors of Labopharm, said, "Jim has been a positive influence on Labopharm and has made significant contributions to our Board since joining in 2001. We have benefited greatly from his insights and we wish him well in his future endeavours."

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel SARI containing trazodone for the treatment of major depressive disorder is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Labopharm Reports Results for Third Quarter Fiscal 2008
2. Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
3. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
4. Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
5. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
6. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
7. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
8. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
9. Labopharm Reports Results for First Quarter Fiscal 2008
10. Labopharm announces details for first quarter results conference call and annual meeting
11. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... MI (PRWEB) , ... March 24, 2017 , ... ... assistance, financial planning, and related services to families and business owners across eastern ... aimed at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy at the HyGIeaCare® ... Centers in 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a ... will interrelate. “End Time GPS” is the creation of published author, Wesley Gerboth, ... working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares the ...
(Date:3/23/2017)... & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... health emergency and now estimates that there could be four million Zika-related cases in ... epidemics to date with numbers of US cases reported per year skyrocketing to an ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... NEW YORK and GENEVA ... Agreement announced on World Tuberculosis Day revitalizes efforts to ...   On World Tuberculosis Day, TB Alliance ... agreement for the clinical development of sutezolid, an antibiotic ... The sublicense pertains to the development of sutezolid in ...
(Date:3/23/2017)... The key factors driving the growth ... accelerating economic growth and increasing healthcare expenditure. Some of the ... expectancy of ESRD patients, rising demand for home PD treatment ... of the market is hindered by high treatment costs and ... ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli Lilly ... William Sansum Diabetes Center have established a research collaboration ... diabetes through enhanced research, education and care. ... bears a disproportionate weight on Latino families in ... Kerr , M.D., FRCPE, director of Innovation and Research ...
Breaking Medicine Technology: